XORTX Therapeutics Inc. Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Property and equipment

Property and equipment

12 Months Ended

Dec. 31, 2025

9.Property and equipment


		Right-of-use
Cost		asset	Equipment	Total
		$	$	$
Balance, December 31, 2023		114,588	23,344	137,932
Additions		96,998	—	96,998
Balance, December 31, 2024		211,586	23,344	234,930
Additions		88,074	—	88,074
Balance, December 31, 2025		299,660	23,344	323,004


		Right-of-use
Accumulated amortization		asset	Equipment	Total
		$	$	$
Balance, December 31, 2023		103,675	10,330	114,005
Amortization		78,525	7,679	86,204
Balance, December 31, 2024		182,200	18,009	200,209
Amortization		80,763	4,967	85,730
Balance, December 31, 2025		262,963	22,976	285,939

9.Property and equipment (continued)


		Right-of-use
Carrying values		asset	Equipment	Total
		$	$	$
At December 31, 2024		29,386	5,335	34,721
At December 31, 2025		36,697	368	37,065

The Company entered into an office lease during the year ended December 31, 2022 for which a right-of-use asset was recognized (Note 11). During the year ended December 31, 2025, the Company extended its office lease. A $88,074 right - of - use asset addition was recognized with a corresponding $88,074 increase to the lease liability.